FibroGen, Inc.
- Country
- 🇺🇸United States
- Ownership
- Public
- Established
- 1993-01-01
- Employees
- 486
- Market Cap
- $38.6M
- Website
- http://www.fibrogen.com
A Study of FG-3246 in Participants With Metastatic Castration-Resistant Prostate Cancer (mCRPC)
- Conditions
- Metastatic Castration-Resistant Prostate Cancer
- Interventions
- First Posted Date
- 2025-03-25
- Last Posted Date
- 2025-04-02
- Lead Sponsor
- FibroGen
- Target Recruit Count
- 75
- Registration Number
- NCT06842498
- Locations
- 🇺🇸
Astera Cancer Care, East Brunswick, New Jersey, United States
A Study to Evaluate the Efficacy and Safety of Roxadustat for the Treatment of Anemia in Participants Receiving Chemotherapy Treatment for Non-Myeloid Malignancies
- First Posted Date
- 2022-03-29
- Last Posted Date
- 2023-06-06
- Lead Sponsor
- FibroGen
- Target Recruit Count
- 159
- Registration Number
- NCT05301517
- Locations
- 🇨🇳
Shandong First Medical University Cancer Hospital, Jinan, China
🇨🇳The Second Hospital of Lanzhou University, Lanzhou, China
🇨🇳Neijiang Second People's Hospital, Neijiang, China
Phase 3 Trial of Pamrevlumab or Placebo in Combination With Systemic Corticosteroids in Participants With Ambulatory DMD
- Conditions
- Duchenne Muscular Dystrophy
- Interventions
- First Posted Date
- 2020-11-17
- Last Posted Date
- 2024-08-26
- Lead Sponsor
- FibroGen
- Target Recruit Count
- 73
- Registration Number
- NCT04632940
- Locations
- 🇺🇸
Seattle Children's Hospital, Seattle, Washington, United States
🇺🇸University of California San Diego Health, San Diego, California, United States
🇺🇸Cincinnati Children's Hospital Medical Center, Cincinnati, Ohio, United States
Investigating the Efficacy, Safety and PK of Roxadustat (FG-4592) for Treatment of Anemia in Pediatric Patients With CKD
- Conditions
- Anemia Associated With Chronic Kidney Disease
- Interventions
- First Posted Date
- 2020-11-09
- Last Posted Date
- 2022-07-05
- Lead Sponsor
- FibroGen
- Registration Number
- NCT04621331
- Locations
- 🇺🇸
University of Nebraska Medical Center, Omaha, Nebraska, United States
🇺🇸Ann and Robert H. Lurie Children's Hospital of Chicago, Chicago, Illinois, United States
🇺🇸Icahn School of Medicine at Mount Sinai (ISMMS) - The Mount Sinai Hospital (MSH), New York, New York, United States
Study of Roxadustat Conversion in Participants Receiving Stable ESA or as Initial Anemia Treatment in Hemodialysis Participants
- Conditions
- Anemia Associated With End Stage Renal Disease
- Interventions
- First Posted Date
- 2020-07-24
- Last Posted Date
- 2022-07-26
- Lead Sponsor
- FibroGen
- Target Recruit Count
- 283
- Registration Number
- NCT04484857
- Locations
- 🇺🇸
Investigational Site, Norfolk, Virginia, United States
🇺🇸Investigator Site, San Antonio, Texas, United States
🇺🇸Investigator Sites, San Antonio, Texas, United States
Study of the Efficacy and Safety of Intravenous Pamrevlumab, in Hospitalized Participants With Acute COVID-19 Disease
- First Posted Date
- 2020-06-16
- Last Posted Date
- 2022-07-18
- Lead Sponsor
- FibroGen
- Target Recruit Count
- 22
- Registration Number
- NCT04432298
- Locations
- 🇺🇸
Research Center, Philadelphia, Pennsylvania, United States
Zephyrus II: Efficacy and Safety Study of Pamrevlumab in Participants With Idiopathic Pulmonary Fibrosis (IPF)
- First Posted Date
- 2020-06-05
- Last Posted Date
- 2024-08-12
- Lead Sponsor
- FibroGen
- Target Recruit Count
- 372
- Registration Number
- NCT04419558
- Locations
- 🇳🇱
Longarts - Opleider Longziekten Zuyderland MC, Heerlen, Netherlands
🇺🇸University of Minnesota, Minneapolis, Minnesota, United States
🇬🇧University College London, London, United Kingdom
Study of Roxadustat Conversion in Participants Receiving Stable Erythropoiesis-Stimulating Agent (ESA) or as Initial Anemia Treatment in Chronic Dialysis Participants
- Conditions
- Anemia Associated With End Stage Renal Disease (ESRD)
- Interventions
- First Posted Date
- 2020-06-01
- Last Posted Date
- 2022-09-13
- Lead Sponsor
- FibroGen
- Target Recruit Count
- 203
- Registration Number
- NCT04410198
- Locations
- 🇺🇸
Investigational Site, Saint George, Utah, United States
Phase 3 Trial of Pamrevlumab or Placebo With Systemic Corticosteroids in Participants With Non-ambulatory Duchenne Muscular Dystrophy (DMD)
- Conditions
- Duchenne Muscular Dystrophy
- Interventions
- First Posted Date
- 2020-05-01
- Last Posted Date
- 2024-03-12
- Lead Sponsor
- FibroGen
- Target Recruit Count
- 98
- Registration Number
- NCT04371666
- Locations
- 🇺🇸
Rare Disease Research, LLC, Atlanta, Georgia, United States
🇺🇸Kennedy Krieger Institute, Baltimore, Maryland, United States
🇺🇸Vanderbilt University Medical Center, Nashville, Tennessee, United States
Evaluation of Efficacy and Safety of Roxadustat for the Treatment of Chemotherapy Induced Anemia
- First Posted Date
- 2019-09-04
- Last Posted Date
- 2022-06-03
- Lead Sponsor
- FibroGen
- Target Recruit Count
- 92
- Registration Number
- NCT04076943
- Locations
- 🇺🇸
Research Center, Philadelphia, Pennsylvania, United States